Table 2.
Brand Name | Generic Name | Main Indications | Designation (Year) | Global Salesa 2010 (Million) |
---|---|---|---|---|
Humira | Adalimumab | Inflammatory bowel diseases, Juvenile rheumatoid arthritis | 2005* | 6,548 |
Fosamax b | Alendronate | Osteogenesis Imperfecta | 2001 | - |
Ceredase# | Alglucerase | Type I, II, III Gaucher’s disease | 1985* | 720 |
Abilify | Aripiprazole | Tourette’s syndrome | 2006 | 2,565 |
Avastin | Bevacizumab | Chemotherapy for cancers | 2003 | 7,178 |
Velcade | Bortezomib | Multiple myeloma, lymphomas | 2003* | - |
Tracleer | Bosentan | Pulmonary artery hypertension, Idiopathic pulmonary fibrosis | 2000* | - |
Botox | Botulinum toxin | Cerebral palsy, Dystonia | 1984* | 1,414 |
Novoseven | Factor VIIa | Hemophilia, Factor VII deficiency, Intracranial hemorrphage | 1988* | 1,483 |
Epogen | Epoetin alfa | Anemia related to HIV infection,, Anemia in end stage renal disease, | 1986* | 2,524 |
Procrit | Epoetin alfa | Anemia related to HIV infection,, Anemia in end stage renal disease, | 1987 | 1,934 |
Enbrel | Etanercept | Juvenile rheumatoid arthritis, Wegener’s granulomatosis | 1998* | 7,287 |
Neupogen | Filgrastim | Neutropenia in various conditions | 1990* | 1,286 |
Neurontin b | Gabapentin | Treatment of ALS | 1995 | 823 |
Copaxone | Glatiramer | Multiple sclerosis | 1987* | 3,300 |
Gleevec | Imatinib | Acute and chronic leukemia | 2001* | 4,265 |
Cerezyme# | Imiglucerase | Type I, II, III Gaucher’s disease | 1991* | 720 |
Remicade | Infliximab | Inflammatory bowel diseases, | 1995* | 6,565 |
Betaseron | IFN beta-1b | Multiple sclerosis | 1988* | 1,658 |
Avonex | IFN beta-1a | Multiple sclerosis | 1991* | 2,518 |
Rebif | IFN beta-1a | Multiple sclerosis | 1992 | 2,297 |
Lamictal b | Lamotrigine | Lennox-Gastaut Sundrome | 1995* | 671 |
Revlimid | Lenalidomide | Multiple myeloma, Lymphoma, Leukemia | 2001* | - |
Lupron | Leuprolide | Precocious puberty | 1988* | 1,617 |
Mobic | Meloxicam | Juvenile rheumatoid arthritis | 2002* | |
Provigil b | Modafinil | Narcolepsy | 1993* | 999 |
CellCept | Mycophenolate | Pemphigus vulgaris, MG | 2006 | 1,433 |
Sandostatin | Octreotide | Acromegaly | 1998* | 1,291 |
Kogenate | Octocog | Hemophilia | 1989* | 1,380 |
Taxol | Paclitaxel | Kaposi’s sarcoma | 1997* | - |
Pegasys | IFN alfa-2a | Renal cell carcinoma, CML | 1998 | 1,828 |
Alimta | Pemetrexed | Malignant mesothelioma | 2001* | - |
Mirapex b | Pramipexole | Tourette’s syndrome | 2008 | - |
Evista | Raloxifene | Postmenopausal breast cancer | 2005* | - |
Rituxan | Rituximab | NHL, chronic leukemia, vasculitis | 1994* | 7,061 |
Vioxx | Rofecoxib | Juvenile rheumatoid arthritis | 2004 | - |
Prograf | Tacrolimus | Graft-versus-host-disease | 1998* | - |
Cialis | Tadalafil | Pulmonary artery hypertension | 2006 | 1,699 |
Temodar | Temozolomide | Malignant glioma, Metastatin melanoma | 1998* | 1,065 |
Spiriva | Tiotropium | Cystic fibrosis (conjuctive therapy) | 2008 | 3,935 |
Topamax b | Topiramate | Lennox-Gastaut Sundrome | 1992* | - |
Herceptin | Trastuzumab | Pancreatic cancer | 1999 | 6,032 |
Zometa | Zoledronic acid | Tumor induced hypercalcemia | 2000* | 1,511 |
Sources: FDA, Pipeline Review, Drug Topics, and Pharmacy Times
Numbers represent million dollars
Generic formulation is now available
Received orphan approval
Similar products
ALS = Amyotrophic Lateral Sclerosis, CML = Chronic Myeloid Leukemia, HIV = Human Immunodeficiency Virus, IFN = Interferon, MG = Myasthenia Gravis, NHL = Non-Hodgkin’s lymphoma.